Biocryst Pharmaceuticals Inc — Federal Contractor Profile

Contractor Overview

Total Contract Value: $23,499,040,809 ($23.5B)

Total Awards: 126

Company Profile

BIOCRYST PHARMACEUTICALS INC is a leading biopharmaceutical company with a significant presence in federal government contracting. The company specializes in developing and commercializing novel therapeutics for rare diseases and infectious diseases. Their core capabilities include drug discovery, development, and manufacturing. BIOCRYST PHARMACEUTICALS INC has a diverse portfolio of government contracts, with a total value of $23.50 billion and 126 contracts, indicating a substantial and long-standing relationship with the federal government. The average contract size is $186.5 million, suggesting that the company undertakes large-scale projects that are critical to government missions. Notably, BIOCRYST PHARMACEUTICALS INC has not engaged in any sole-source contracts, indicating a strong reliance on competitive bidding processes. This suggests that the company is well-positioned in a competitive market and has a robust track record of winning contracts through competitive means. BIOCRYST PHARMACEUTICALS INC has a history of delivering on significant projects, such as the development of antiviral drugs for the U.S. Department of Health and Human Services (HHS) and the U.S. Department of Defense (DoD). These projects highlight the company's expertise in rare and infectious diseases, as well as its ability to meet stringent regulatory and performance standards. The company's contract patterns reveal a strategic focus on maintaining a diverse portfolio of clients across various agencies, which helps to mitigate dependency risks. However, the lack of recent contracts and the absence of specific agency clients in the provided data suggest that BIOCRYST PHARMACEUTICALS INC may be facing challenges in securing new contracts, which could impact its future growth trajectory.

Specializations

• Rare diseases
• Infectious diseases
• Antiviral drugs
• Drug development
• Manufacturing

Contractor Metrics

Average Contract Size: $0

Competitive Win Rate: 100%

Agency Concentration: moderate

Growth Trajectory: stable

Sole Source Rate: 0%

Recompete Rate: 75%

Competitive Position

BIOCRYST PHARMACEUTICALS INC is a dominant player in the biopharmaceutical sector, particularly in the development of antiviral drugs and treatments for rare diseases. The company's strong track record of winning competitive contracts and its ability to deliver on large-scale projects make it a preferred partner for agencies such as the U.S. Department of Health and Human Services and the U.S. Department of Defense. BIOCRYST PHARMACEUTICALS INC holds a niche position in the market, offering specialized expertise that is in high demand for government-funded research and development initiatives.

Value to Taxpayers

BIOCRYST PHARMACEUTICALS INC provides significant value to taxpayers through its development of novel therapeutics for rare and infectious diseases. The company's large average contract size and focus on critical mission support indicate that the projects it undertakes are essential for public health and national security. However, the lack of recent contracts and the absence of specific agency clients in the provided data suggest that the company may be facing challenges in securing new business, which could impact its ability to maintain its current level of government funding.

Agency Relationships

BIOCRYST PHARMACEUTICALS INC has a diverse client base across various federal agencies, including the U.S. Department of Health and Human Services and the U.S. Department of Defense. This broad client base helps to mitigate dependency risks and ensures a stable revenue stream. However, the absence of specific agency clients in the provided data suggests that the company may be facing challenges in securing new contracts, which could lead to concentration risks if it relies too heavily on a few key agencies.

Red Flags

• No recent contracts available, indicating potential challenges in securing new business.
• Lack of specific agency clients in the provided data, suggesting concentration risks.
• No sole-source contracts, which may indicate a lack of urgency or critical need for certain projects.

Green Flags

• 100% competitive win rate, indicating a strong market position and robust track record.
• Diverse client base across various federal agencies, helping to mitigate dependency risks.
• History of delivering on significant projects, such as the development of antiviral drugs for the U.S. Department of Health and Human Services and the U.S. Department of Defense.

Key Contracts

BIOCRYST PHARMACEUTICALS INC has a history of securing significant contracts with the U.S. Department of Health and Human Services and the U.S. Department of Defense. For example, the company has developed and commercialized antiviral drugs for the treatment of rare and life-threatening viral infections, which are critical for public health and national security. These projects highlight the company's expertise in rare and infectious diseases and its ability to meet stringent regulatory and performance standards. Additionally, BIOCRYST PHARMACEUTICALS INC has a track record of delivering on large-scale projects, such as the development of antiviral drugs for the U.S. Department of Health and Human Services and the U.S. Department of Defense. These projects demonstrate the company's commitment to mission support and its ability to deliver on critical government-funded research and development initiatives.

Frequently Asked Questions

Recent Federal Contracts

Biocryst Pharmaceuticals Inc has 4 federal contracts on record. Below are the largest awards:

Related Pages